- Details
- Description
-
Packaging Size30t
-
Strength0.75mg
-
CompositonAtrasentan
-
TreatmentIgA nephropathy
-
FormTablet
-
BrandLuciAtras
-
Quantity Unit0.75mg*30t/Box
-
ManufacturerLucius Pharmaceuticals (Lao) Co.,Ltd
About Atrasentan
Atrasentan is a medication used to reduce proteinuria.It is an endothelin receptor antagonist. Atrasentan is indicated to reduce proteinuria in adults with primary immunoglobulin A nephropathy at risk of rapid disease progression, generally a urine protein-to-creatinine ratio >= 1.5 g/g.
IgA Nephropathy
Indicated to reduce proteinuria in adults with primary immunoglobulin A nephropathy (IgAN) at risk of rapid disease progression, generally a urine protein-to-creatinine ratio (UPCR) ≥1.5 g/g
0.75 mg PO daily
Dosage Modifications
Renal impairment
- Mild-to-severe (eGFR 15-90 mL/min/1.73 m2): No dose adjustment required
- End-stage renal disease (eGFR <15 mL/min/1.73 m2): Effect unknown
Hepatic impairment
- Mild-to-moderate (Child Pugh A or B): No dose adjustment required
- Severe (Child Pugh C): Do not initiate; effect unknown
